The latest biotech news

News and Trends 12 Mar 2018

FDA Says Dutch Surgical Sealant Patch Could Save Lives

Polyganics has received a Breakthrough Device Designation from the FDA for its biodegradable sealant patch for surgical wounds. Polyganics, based in Groningen, the Netherlands, specializes in medical devices that use natural polymers to help regenerate injured tissue. The FDA granted a Breakthrough Device Designation for its Liver and Pancreas Sealant Patch. The patch uses Polyganics polymer technology to seal […]

March 12, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 12 Mar 2018

We Can Now Make Plastics Out of Old Clothes Using Biology

Carbios, a French biotech, has developed an environmentally-friendly method to break down the PET plastic fibers in textile waste using enzymes. Carbios has developed a technology which can depolymerize textile waste fibers made of PET plastics into their original monomers. The technology uses enzymes to create biodegradable plastics and recycle existing plastics into their original compounds for […]

March 12, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 12 Mar 2018

A Flick of a Switch Can Cause Age-Related Brain Deterioration

Switching certain genes on or off causes the premature aging of stem cells that repair the brain. Identifying them could provide a target for new therapeutic approaches against neurodegenerative diseases. Scientists at the Babraham Insitute in Cambridge and the University of Sapienza in Rome have identified a number of genes involved in the aging of […]

March 12, 2018 - 3 minutesmins - By Alex Dale

bone therapeutics spinal fusion cell therapy

News and Trends 8 Mar 2018

Belgian Firm Raises €19M to Fix Spinal Fusion with Cell Therapy

Bone Therapeutics has raised €19.5M through a private placement that will fund the completion of clinical trials testing its cell therapy for spinal fusion and other bone diseases. Based in Groselies, Belgium, Bone Therapeutics wants to use cell therapy to help people with bone injuries or diseases regenerate healthy bone. In order to complete its […]

March 8, 2018 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 8 Mar 2018

French Biotech Targets Gut Microbiome to Treat Diabetes

Valbiotis has shown that its treatment restores diversity in a population of gut microorganisms imbalanced by type 2 diabetes in mice. Valbiotis, based in Périgny, France, wants to treat type 2 diabetes by restoring the balance of microbial populations in the gut microbiome. New data from a metagenomic sequencing study in mice has shown that its drug, […]

March 8, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 7 Mar 2018

This Spanish Biotech Might Have the First Effective Treatment for a Rare Blood Condition

Sanifit has successfully completed a Phase II trial with what could be the first effective treatment for calciphylaxis, a deadly rare disease caused by calcium accumulation in the blood. Mallorca-based Sanifit is targeting calciphylaxis with its treatment called SNF472. Results from Sanifit’s Phase II trial show that the drug promotes wound healing and reduces pain, though the details […]

March 7, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 7 Mar 2018

Oxford Keeps Growing as a Hotspot for Cancer Vaccines with New Fundraising

Oxford Vacmedix has secured $12.5M (€10M) to start its first clinical trials, joining other Oxford-based biotechs in the cancer vaccine field such as Vaccitech and SpyBiotech. Oxford Vacmedix has secured Series A financing to continue the development of its two lead cancer vaccines to target cervical cancer and other solid tumors. The financing round represents the […]

March 7, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 6 Mar 2018

Oxford Spin-out Moves Gene Therapy For Blindness Into Phase III Trial

Nightstar Therapeutics will begin the first Phase III trial for a gene therapy targeting choroideremia, a rare disorder leading to complete blindness. Nightstar will launch the first-ever Phase III trial testing a gene therapy for choroideremia, a genetic disorder characterized by night blindness and gradual loss of vision that eventually leads to complete blindness. The trial, STAR, […]

March 6, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 6 Mar 2018

Swiss VC Closes €86M Fund for Medical Biotech in Europe

BioMedPartners has raised CHF100M (€86M) that will be invested in medical biotech companies in Switzerland, Germany, and other EU countries. Swiss VC BioMedPartners has managed to gather some big European investors to close its third venture capital fund, called BioMedInvest III and sized at CHF 100M (€86M). Among the investors are the European Investment Fund […]

March 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Mar 2018

French Biotech Uses Natural Peptides to Boost Plant Growth and Immunity

Micropep Technologies, a Toulouse-based biotech, has raised €4M to develop peptides that boost plant growth and disease resistance by regulating gene expression. Micropep Technologies has raised a Series A funding with the support of two new investors, Sofinnova Partners, the largest industrial biotech fund in the world, and Irdi Soridec Gestion. The company aims to use the funding […]

March 6, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 5 Mar 2018

Danish Biotech Starts Phase III Atopic Dermatitis Trial With Failed Asthma Treatment

Danish biotech LEO Pharma started a Phase III trial in atopic dermatitis with an antibody that AstraZeneca dropped after failing two Phase III trials in asthma. LEO Pharma is taking over the development of the antibody tralokinumab from AstraZeneca to treat atopic dermatitis after the drug failed multiple Phase III studies for treating asthma. In […]

March 5, 2018 - 2 minutesmins - By Alexander Burik

santhera multiple sclerosis trial idebenone

News and Trends 5 Mar 2018

Swiss Company Hits Another Slump with a Failed Multiple Sclerosis Trial

Just months after the EMA rejected its therapy for Duchenne muscular dystrophy, Swiss company Santhera reports negative data for its multiple sclerosis drug. Santhera Pharmaceuticals has reported this morning that a first clinical trial in patients with primary progressive multiple sclerosis (PPMS) failed to prove the company’s drug to have any effect on the progression of […]

March 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

FDA Says Dutch Surgical Sealant Patch Could Save Lives

We Can Now Make Plastics Out of Old Clothes Using Biology

A Flick of a Switch Can Cause Age-Related Brain Deterioration

Belgian Firm Raises €19M to Fix Spinal Fusion with Cell Therapy

French Biotech Targets Gut Microbiome to Treat Diabetes

This Spanish Biotech Might Have the First Effective Treatment for a Rare Blood Condition

Oxford Keeps Growing as a Hotspot for Cancer Vaccines with New Fundraising

Oxford Spin-out Moves Gene Therapy For Blindness Into Phase III Trial

Swiss VC Closes €86M Fund for Medical Biotech in Europe

French Biotech Uses Natural Peptides to Boost Plant Growth and Immunity

Danish Biotech Starts Phase III Atopic Dermatitis Trial With Failed Asthma Treatment

Swiss Company Hits Another Slump with a Failed Multiple Sclerosis Trial

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!